Evidence map›Paper›PMID 36032136›Full record

ArticleFrontiers in immunology2022

Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study.

Qianhui Hua, Hangjie Zhang, Pingping Yao, Nani Xu, Yisheng Sun, Hangjing Lu, Fang Xu, Yuting Liao, Juan Yang, Haiyan Mao and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Qianhui HuaSchool of Medicine, Ningbo University, Ningbo, China.
Hangjie ZhangDepartment of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Pingping YaoDepartment of Virus Inspection, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Nani XuDepartment of Immunization Program, Xihu District Center for Disease Control and Prevention, Hangzhou, China.
Yisheng SunDepartment of Virus Inspection, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Hangjing LuDepartment of Virus Inspection, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Fang XuDepartment of Virus Inspection, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Yuting LiaoState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.
Juan YangState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.
Haiyan MaoDepartment of Virus Inspection, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Yanjun ZhangDepartment of Virus Inspection, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Hanping ZhuDepartment of Virus Inspection, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Xiaowei HuDepartment of Immunization Program, Xihu District Center for Disease Control and Prevention, Hangzhou, China.
Huakun LvDepartment of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Jianmin JiangDepartment of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Zhejiang Center for Disease Control and Prevention · CNHangzhou Center for Disease Control and Prevention · CNXiamen University · CNNingbo University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Owing to the coronavirus disease 2019 (COVID-19) pandemic and the emergency use of different types of COVID-19 vaccines, there is an urgent need to consider the effectiveness and persistence of different COVID-19 vaccines. Methods: We investigated the immunogenicity of CoronaVac and Covilo, two inactivated vaccines against COVID-19 that each contain inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The levels of neutralizing antibodies to live SARS-CoV-2 and the inhibition rates of neutralizing antibodies to pseudovirus, as well as the immunoglobulin (Ig)G and IgM responses towards the spike (S) and nucleocapsid (N) protein of SARS-CoV-2 at 180 days after two-dose vaccination were detected. Results: The CoronaVac and Covilo vaccines induced similar antibody responses. Regarding neutralizing antibodies to live SARS-CoV-2, 77.9% of the CoronaVac vaccine recipients and 78.3% of the Covilo vaccine recipients (aged 18-59 years) seroconverted by 28 days after the second vaccine dose. Regarding SARS-CoV-2-specific antibodies, 97.1% of the CoronaVac vaccine recipients and 95.7% of the Covilo vaccine recipients seroconverted by 28 days after the second vaccine dose. The inhibition rates of neutralizing antibody against a pseudovirus of the SARS-CoV-2 Delta variant were significantly lower compared with those against a pseudovirus of wildtype SARS-CoV-2. Associated with participant characteristics and antibody levels, persons in the older age group and with basic disease, especially a chronic respiratory disease, tended to have lower anti-SARS-CoV-2 antibody seroconversion rates. Conclusion: Antibodies that were elicited by these two inactivated COVID-19 vaccines appeared to wane following their peak after the second vaccine dose, but they persisted at detectable levels through 6 months after the second vaccine dose, and the effectiveness of these antibodies against the Delta variant of SARS-CoV-2 was lower than their effectiveness against wildtype SARS-CoV-2, which suggests that attention must be paid to the protective effectiveness, and its persistence, of COVID-19 vaccines on SARS-CoV-2 variants.

Indexed as

COVID-19Viral VaccinesAgedAntibodies, NeutralizingAntibodies, ViralAttentionCohort StudiesCOVID-19 VaccinesHumansImmunoglobulin GSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GViral VaccinesCOVID-19dynamic changesimmunogenicityinactivated vaccinepersistenceSARS-CoV-2

Identifiers

PMID36032136
PMCPMC9411798
OpenAlexW4291123977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.